Latest Novartis Media Releases in English en http://www.novartis.com Copyright (c)2005 Novartis International AG http://blogs.law.harvard.edu/tech/rss Hugin - http://www.hugingroup.com/ webmaster@novartis.com webmaster@novartis.com Wed, 1 Jul 2009 02:11:07 +0200 10 http://www.novartis.com/images/novartis_logo.jpg http://www.novartis.com 195 98 Wed, 1 Jul 2009 02:10:21 +0200 http://cws.huginonline.com/N/134323/PR/200907/1326284_5.html Novartis International AG Fri, 26 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1325101_5.html Novartis International AG Thu, 25 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1324821_5.html Novartis International AG Wed, 24 Jun 2009 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1324661_5.html Novartis International AG Thu, 18 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1323528_5.html Novartis International AG Fri, 12 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1322241_5.html Novartis International AG Mon, 8 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1320856_5.html Novartis International AG Fri, 5 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1320149_5.html Novartis International AG Thu, 4 Jun 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1319838_5.html Novartis International AG Wed, 3 Jun 2009 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1319771_5.html Novartis International AG Tue, 2 Jun 2009 18:02:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1319318_5.html Novartis International AG Mon, 1 Jun 2009 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200906/1318842_5.html Novartis International AG Fri, 29 May 2009 18:24:32 +0200 http://cws.huginonline.com/N/134323/PR/200905/1318767_5.html Novartis International AG Thu, 28 May 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1318019_5.html Novartis International AG Thu, 28 May 2009 02:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1318048_5.html Novartis International AG Tue, 26 May 2009 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1317593_5.html Novartis International AG Thu, 21 May 2009 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1316936_5.html Novartis International AG Wed, 20 May 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1316498_5.html Novartis International AG Tue, 19 May 2009 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1316055_5.html Novartis International AG Thu, 14 May 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1314777_5.html Novartis International AG Wed, 13 May 2009 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1314511_5.html Novartis International AG Wed, 13 May 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1314149_5.html Novartis International AG Thu, 7 May 2009 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200905/1311895_5.html Novartis International AG Thu, 30 Apr 2009 22:05:00 +0200 http://cws.huginonline.com/N/134323/PR/200904/1310474_5.html Novartis International AG Thu, 30 Apr 2009 08:18:20 +0200 http://cws.huginonline.com/N/134323/PR/200904/1310049_5.html Novartis International AG Wed, 29 Apr 2009 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200904/1309396_5.html Novartis International AG Thu, 23 Apr 2009 06:59:00 +0200 http://cws.huginonline.com/N/134323/PR/200904/1307495_5.html Novartis International AG Wed, 8 Apr 2009 18:40:20 +0200 http://cws.huginonline.com/N/134323/PR/200904/1304377_5.html Novartis International AG Thu, 2 Apr 2009 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200904/1303085_5.html Novartis International AG Mon, 30 Mar 2009 23:27:57 +0200 http://cws.huginonline.com/N/134323/PR/200903/1301829_5.html Novartis International AG Mon, 30 Mar 2009 21:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200903/1301801_5.html Novartis International AG Wed, 25 Mar 2009 02:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200903/1300166_5.html Novartis International AG Thu, 19 Mar 2009 17:43:00 +0100 http://cws.huginonline.com/N/134323/PR/200903/1299087_5.html Novartis International AG Wed, 18 Mar 2009 23:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200903/1298635_5.html Novartis International AG Tue, 24 Feb 2009 17:35:00 +0100 http://cws.huginonline.com/N/134323/PR/200902/1292900_5.html Novartis International AG Fri, 13 Feb 2009 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200902/1290168_5.html Novartis International AG Thu, 12 Feb 2009 06:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200902/1289667_5.html Novartis International AG Wed, 11 Feb 2009 23:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200902/1289425_5.html Novartis International AG Thu, 5 Feb 2009 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200902/1287646_5.html Novartis International AG Wed, 28 Jan 2009 06:59:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1285325_5.html Novartis International AG Tue, 27 Jan 2009 22:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1285136_5.html Novartis International AG Tue, 27 Jan 2009 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1284997_5.html Novartis International AG Thu, 22 Jan 2009 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1283987_5.html Novartis International AG Wed, 21 Jan 2009 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1283705_5.html Novartis International AG Thu, 15 Jan 2009 16:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1282432_5.html Novartis International AG Wed, 14 Jan 2009 00:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1281971_5.html Novartis International AG Wed, 14 Jan 2009 00:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200901/1281970_5.html Novartis International AG Mon, 29 Dec 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1279693_5.html Novartis International AG Sat, 20 Dec 2008 02:14:19 +0100 http://cws.huginonline.com/N/134323/PR/200812/1279094_5.html Novartis International AG Sat, 13 Dec 2008 00:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1277244_5.html Novartis International AG Fri, 12 Dec 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1277020_5.html Novartis International AG Thu, 11 Dec 2008 21:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1276910_5.html Novartis International AG Thu, 11 Dec 2008 16:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1276719_5.html Novartis International AG Thu, 11 Dec 2008 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1276717_5.html Novartis International AG Tue, 9 Dec 2008 00:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1275815_5.html Novartis International AG Mon, 8 Dec 2008 22:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1275790_5.html Novartis International AG Thu, 4 Dec 2008 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1275054_5.html Novartis International AG Thu, 4 Dec 2008 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1274761_5.html Novartis International AG Thu, 4 Dec 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200812/1275058_5.html Novartis International AG Fri, 21 Nov 2008 12:48:00 +0100 http://cws.huginonline.com/N/134323/PR/200811/1272071_5.html Novartis International AG Fri, 21 Nov 2008 12:46:24 +0100 http://cws.huginonline.com/N/134323/PR/200811/1272035_5.html Novartis International AG Wed, 19 Nov 2008 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200811/1271207_5.html Novartis International AG Tue, 11 Nov 2008 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200811/1268561_5.html Novartis International AG Wed, 29 Oct 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200810/1264205_5.html Novartis International AG Mon, 27 Oct 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200810/1263270_5.html Novartis International AG Tue, 21 Oct 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200810/1261361_5.html Novartis International AG Mon, 20 Oct 2008 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200810/1260877_5.html Novartis International AG Wed, 8 Oct 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200810/1257684_5.html Novartis International AG Tue, 7 Oct 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200810/1257283_5.html Novartis International AG Mon, 6 Oct 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200810/1257049_5.html Novartis International AG Tue, 30 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1255392_5.html Novartis International AG Thu, 25 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1254262_5.html Novartis International AG Fri, 19 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1252754_5.html Novartis International AG

New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 versus 1.9 months with placebo

One quarter of patients in trial remained progression-free beyond ten months of treatment

RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent® or Nexavar®**, with potential to address unmet medical need

RAD001 (proposed brand name Afinitor®) under review by regulatory authorities; potential to be first once-daily oral mTOR therapy for advanced kidney cancer

]]> Tue, 16 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1251556_5.html Novartis International AG

Coartem achieves high cure rates in studies[1],[2] and since 2001 has helped save an estimated 500,000 lives

Priority review by FDA underscores urgency of stopping malaria - a key goal of US President's Malaria Initiative

Working with international community, Novartis has supplied more than 195 million treatments to malaria-endemic countries without profit

]]> Mon, 15 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1251164_5.html Novartis International AG

82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR

77% of patients with pancreatic NET experienced clinical benefit when treated with daily RAD001

Data show RAD001, an oral mTOR inhibitor, has potential to become new treatment for patients with pancreatic NET who currently have limited options

Phase III trials underway to confirm impact of combination RAD001 and Sandostatin LAR therapy on survival in pancreatic NET and carcinoid patients

]]> Sat, 13 Sep 2008 12:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1251089_5.html Novartis International AG

Novel vaccine produced protective immune response against broad range of representative meningococcal B strains in more than 95% of infants tested[1]

Novartis MenB vaccine could fill major unmet need for broadly protective vaccine for children and infants two months and older

Meningococcal B strains cause 72% of meningococcal disease in Europe and 28% in the US; infants and toddlers are the age group most at risk[2], [3]

]]> Wed, 10 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1250239_5.html Novartis International AG

GALIANT[*] study in more than 2,400 patients shows Galvus as effective as commonly prescribed TZD drugs when added to metformin[1]

New pooled data show Galvus is associated with lower overall incidence of cardiovascular and cerebrovascular events, such as heart attacks and strokes, than placebo[2] and confirm good tolerability in patients with mild-to-moderate renal impairment[3]

Patients tolerated Galvus better than TZDs and did not gain weight - a common side effect of other type 2 diabetes medicines[1]

Galvus demonstrates strong efficacy in broad patient population with over 14,000 patients treated in clinical program to date

]]> Tue, 9 Sep 2008 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1249901_5.html Novartis International AG

Regulatory applications to be submitted worldwide for RAD001, proposed brand name Afinitor®; first submissions filed in the US, EU and Switzerland

Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The Lancet

RAD001 shows promise to become first once-daily oral therapy targeting mTOR to treat advanced kidney cancer

]]> Tue, 9 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1249860_5.html Novartis International AG

Data presented at European Society of Cardiology congress confirm Rasilez is effective in difficult-to-treat patients with obesity, heart failure and diabetes[1],[2],[3]

Data from ALOFT study shows Rasilez reduces marker of heart failure severity when added to optimal therapy in chronic heart failure patients with diabetes[2]

Findings important as 70% of patients with high blood pressure are overweight or obese[4] and 23 million people worldwide have chronic heart failure[5]

Heart and kidney protection potential of Rasilez independent of blood pressure lowering ability being further studied in ASPIRE HIGHER clinical program

]]> Wed, 3 Sep 2008 12:35:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1248468_5.html Novartis International AG

New 10mg strength offers increased treatment flexibility and more convenient dosage form

Comparable quality, safety and efficacy combined with significant cost savings

Approval further demonstrates Sandoz leadership in high quality follow-on biologics

]]> Wed, 3 Sep 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200809/1248342_5.html Novartis International AG

Aurograb(TM) decision reached after Phase II results show lack of efficacy as an add -on therapy for life-threatening bacterial infections

USD 235 million impairment charge to be taken in 2008 third quarter results

Mycograb(TM) continues in Phase III trials for treatment of severe fungal infections

]]> Fri, 29 Aug 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200808/1247203_5.html Novartis International AG

Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Glivec after surgery are basis for FDA, EMEA, Swissmedic filings

Historically, one in two patients experienced recurrence of GIST after surgery

Regulatory submissions reflect continued commitment to bringing new therapeutic approaches to patients with rare diseases

]]> Wed, 27 Aug 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200808/1246407_5.html Novartis International AG

Lucentis is only approved therapy to demonstrate improvement in vision and vision-related function in vast majority of wet AMD patients

NICE decision secures access to innovative medication for eligible patients with wet AMD in England and Wales

]]> Wed, 27 Aug 2008 01:02:00 +0200 http://cws.huginonline.com/N/134323/PR/200808/1246393_5.html Novartis International AG

Delivery of Fluvirin supports planning and scheduling of public health influenza vaccination efforts

At least 20 million doses available by the end of September, when widespread vaccination campaigns usually begin

Additional manufacturing capacity recently approved by FDA for Fluvirin pre-filled syringes

]]> Thu, 7 Aug 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200808/1241557_5.html Novartis International AG

Approvals consistent with current US treatment guidelines to start appropriate patients on combination therapies[1]

Up to 80% of patients may need multiple medications to help them reach blood pressure goals[2]

Single-pill combinations offer effective, convenient medications which could help patients reach treatment goals faster[3]

High blood pressure is one of the most important but treatable risk factors for cardiovascular disease - the world's leading cause of death[4]

]]> Mon, 4 Aug 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200808/1239786_5.html Novartis International AG

New data show that patients on Exforge with baseline blood pressure >=180 mmHg experienced significant reductions of up to 40 mmHg to help reach target levels[1]

Significant blood pressure reductions seen with Exforge across difficult-to-treat groups such as the elderly, obese and people with diabetes[1]

High blood pressure is a leading but treatable risk factor for cardiovascular disease - the world's leading cause of death[2]

]]> Mon, 28 Jul 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1238536_5.html Novartis International AG

Male indication important as osteoporosis often neglected in men - estimated one in five men aged over 50 may suffer an osteoporosis-related fracture[1]

Positive opinion also expands once-yearly Aclasta indication to include osteoporosis patients who recently suffered a low-trauma hip fracture

EU label to include data showing 35% reduction in new fractures and 28% reduction of all-cause mortality[2] in post-hip fracture patients treated with Aclasta

Recommendation comes shortly after similar change to US label for Reclast[3][*]

]]> Fri, 25 Jul 2008 12:37:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1238453_5.html Novartis International AG

First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics

Net sales rise 11% (+2% in local currencies) to USD 20.6 billion

Operating income advances 12% to USD 4.9 billion on business expansion, productivity gains and currency benefits

Net income up 13% to USD 4.6 billion; basic EPS rises 17% to USD 2.01

Dynamic growth from new products - including Tekturna/Rasilez, Exforge, Lucentis, Exelon Patch and Aclasta/Reclast - provides USD 1.3 billion in first-half net sales

Key R&D projects on track for 2008 submissions, particularly Afinitor (RAD001) for advanced kidney cancer and Menveo meningococcal meningitis vaccine

25% stake in Alcon, the world leader in eye care, purchased in July; strategic acquisitions strengthen portfolio and complement internal growth drivers

Novartis on track for record sales and earnings in 2008 from continuing operations

]]> Thu, 17 Jul 2008 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1236488_5.html Novartis International AG

Alliance enables Novartis to rapidly scale up development and production for rich biological pipeline, which accounts for a quarter of its development portfolio

Strong Novartis R&D capabilities coupled with Lonza's leadership in process development and manufacturing, provides ideal long-term partnership

]]> Fri, 11 Jul 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1235238_5.html Novartis International AG

Novartis and Speedel have a long-standing collaboration based on financial support for Speedel creation in 1998 and development of Tekturna/Rasilez

Speedel pipeline provides access to many R&D projects targeting cardiovascular disease, including a range of direct renin inhibitors

Ownership of Speedel provides greater flexibility and speed in development of Tekturna/Rasilez and also ends royalty and manufacturing fee payments

After acquiring a 51.7% stake directly from major Speedel shareholders for CHF 130 per share in cash, Novartis now holds 61.4% of Speedel

Novartis will commence a mandatory tender offer to acquire the remaining Speedel shares at the same price

]]> Thu, 10 Jul 2008 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1234914_5.html Novartis International AG

Strong strategic fit with Novartis thanks to Alcon's pharmaceutical, surgical and consumer eye care products businesses

]]> Tue, 8 Jul 2008 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1234280_5.html Novartis International AG

Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damages

Jury decides in favor of Novartis and rejects claims for punitive damages

NPC maintains it reported true and accurate prices and will file appeal

]]> Wed, 2 Jul 2008 01:16:00 +0200 http://cws.huginonline.com/N/134323/PR/200807/1232992_5.html Novartis International AG

The NITD and the TB Alliance's collaboration aims to move projects quickly from the research phase through the translational stage and into development

Both partners will leverage their broad networks of expertise and resources to rapidly bring effective, simpler treatments to patients

]]> Tue, 24 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1230343_5.html Novartis International AG

Novartis to study organ protection potential of Rasilez beyond documented ability to provide powerful blood pressure reductions that last beyond 24 hours[1],[2]

Three megatrials explore Rasilez benefits in difficult-to-treat patients with life-threatening co-morbidities - heart failure, cardiovascular events in elderly and diabetic kidney disease

Data presented at "Hypertension 2008" congress highlight impressive efficacy of Rasilez in managing high blood pressure in elderly, the fastest growing patient demographic segment with climbing healthcare costs[3],[4],[5]

]]> Tue, 17 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1228485_5.html Novartis International AG

Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Glivec as standard of care

Study did not meet primary endpoint at 1 year, yet shows faster time to molecular responses with 800 vs. 400 mg dose

Findings reinforce that monitoring blood levels of Glivec may help optimize treatment benefit for individual patients

Novartis committed to improving first-line treatment through additional study follow-up and completing enrollment to Tasigna vs. Glivec trial

]]> Fri, 13 Jun 2008 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1227552_5.html Novartis International AG

Conditional offer made by TRC Capital Corporation for up to two million Novartis American Depositary Shares

Novartis recommends against shareholders tendering their shares in response to TRC Capital's unsolicited mini-tender offer

]]> Thu, 12 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1227249_5.html Novartis International AG

First bond offering ever by Novartis in Swiss francs sees very strong demand and ranks as the largest-ever corporate offering in the Swiss franc market

Two benchmark bonds offered - a domestic seven-year bond and a four-year bond in the international market segment

]]> Tue, 10 Jun 2008 20:07:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1226826_5.html Novartis International AG

First study to show Diovan/HCT improves artery elasticity in patients with type 2 diabetes, high blood pressure and kidney disease[1]

Diovan/HCT demonstrated superior benefits on artery elasticity, a strong predictor of increased risk of stroke and heart attack[2], compared to amlodipine

Diovan/HCT lowered albumin excretion rate, a key marker of kidney disease, by 35% compared to a rise of 24% with amlodipine[1]

Diovan is the world's number one branded high blood pressure medicine[3]

]]> Thu, 5 Jun 2008 15:16:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1225571_5.html Novartis International AG

Revised label includes data showing 35% reduction in new clinical fractures in patients treated with Reclast following recent hip fracture[1]

Few patients currently receive osteoporosis treatment following hip fracture despite high risk of morbidity and mortality[2]

Safety and efficacy profile of Reclast, already approved for treatment of postmenopausal osteoporosis[1], reinforced in revised label

]]> Thu, 5 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1225355_5.html Novartis International AG

AVOID study shows potential kidney protection benefits of Rasilez in type 2 diabetic patients with kidney disease and high blood pressure[1]

Rasilez reduced albuminuria, a key indicator of kidney disease, by an additional 20% when added to maximum dose of angiotensin-receptor blocker losartan[1],[2]

First clinical trial to present data on potential kidney-protective benefits of Rasilez, independent of its proven blood pressure reductions[3]

Damage to kidneys caused by diabetes is leading cause of end-stage renal disease in developed countries[1]

]]> Wed, 4 Jun 2008 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1225277_5.html Novartis International AG

Acquisition of Protez Pharmaceuticals provides rights to PZ-601 and further strengthens specialty medicines development portfolio in hospital infections

PZ-601 a novel broad-spectrum antibiotic in Phase II development against potentially fatal drug-resistant infections - including MRSA and ESBL strains

Antibiotic resistance an important public health problem, estimated to account for more than 100,000 deaths annually in the US and Europe together

Novartis to fully acquire privately-held Protez for initial payment of USD 100 million, potential for up to USD 300 million of additional payments contingent upon success of PZ-601

]]> Wed, 4 Jun 2008 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1224971_5.html Novartis International AG

Late stage development pipeline with Menveo and MenB vaccines creating meningococcal vaccine franchise with strong growth potential

Novartis leverages research excellence with first in class vaccines in early pipeline, preventing infections from Helicobacter pylori, Group B Streptococcus and other pathogens which pose significant public health challenges

]]> Wed, 4 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1224970_5.html Novartis International AG

Randomized Phase II data show RAD001 significantly increased efficacy of letrozole in women with newly diagnosed hormone-positive breast cancer

Phase I studies suggest RAD001 may help overcome a major pathway of resistance to trastuzumab

Novartis to further explore potential of RAD001 in breast cancer by initiating new trial in early 2009

]]> Mon, 2 Jun 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200806/1224201_5.html Novartis International AG

Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone[1]

Findings may allow clinicians to improve standard of care for premenopausal women diagnosed with hormone-sensitive, early-stage breast cancer

These are the first data from a large clinical program exploring the direct anticancer effect of Zometa in breast, lung and prostate cancer

]]> Sat, 31 May 2008 16:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1224091_5.html Novartis International AG

Extavia is Novartis brand for interferon beta-1b - an established therapy with more than 700,000 patient-years' experience to date[1]

Launch of Extavia for early and relapsing forms of multiple sclerosis (MS) planned for US and Europe in first half of 2009

Novartis committed to MS through extensive research and development programs, including novel oral therapy FTY720 currently in Phase III trials

MS, a devastating disease causing progressive disability, affects an estimated 2.5 million people worldwide, including many young adults[2]

]]> Mon, 26 May 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1222369_5.html Novartis International AG

RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%

RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent® or Nexavar®,** with potential to address unmet medical need

Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a protein that controls tumor cell division and blood vessel growth

RAD001 is currently being studied in multiple types of cancer including neuroendocrine, breast, gastric, lung, and lymphoma

]]> Mon, 19 May 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1220385_5.html Novartis International AG

Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer

Plenary session to highlight impact of Zometa®, the leading IV bisphosphonate, on relapse rate of patients with early-stage breast cancer

Four oral sessions to feature RAD001, first oral once-daily continuous inhibitor of mTOR, including first results of RECORD-1 study in renal cell carcinoma

Updated Phase II results with Tasigna® in Philadelphia chromosome-positive chronic myeloid leukemia to be presented

]]> Thu, 15 May 2008 22:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1219879_5.html Novartis International AG

Recently launched in the US, Tekturna HCT is a single-tablet combination of Tekturna®[*] and the diuretic HCT for the treatment of high blood pressure[1]

Both Tekturna HCT and Tekturna provide effective blood pressure lowering with good tolerability[1,2,3]

Tekturna, first-in-class direct renin inhibitor, provides blood pressure reductions that last beyond 24 hours[2,4]

]]> Thu, 15 May 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1219430_5.html Novartis International AG

Data show Novartis Meningitis B (MenB) vaccine has potential to be first vaccine to provide broad protection to infants against meningococcal B infections

The meningococcal B strain causes 72% of meningococcal disease in Europe and is a major cause of the disease in other regions of the world

Novartis MenB vaccine and Novartis Menveo® (MenACWY-CRM) vaccine on track to establish strong portfolio of meningitis vaccines

]]> Wed, 14 May 2008 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1218899_5.html Novartis International AG

Study sub-group with severe high blood pressure shows largest blood pressure drop to date in an Exforge clinical trial[2,3,4]

After only two weeks, Exforge delivered significantly greater reductions in blood pressure than amlodipine alone[1]

20 mmHg decrease in systolic blood pressure halves risk of death from heart disease or stroke[5]

]]> Wed, 14 May 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1218905_5.html Novartis International AG

First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*

Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood

More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo[1]

]]> Tue, 6 May 2008 04:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200805/1216115_5.html Novartis International AG

The Friedrich Miescher Institute of the Novartis Research Foundation (FMI) announces a breakthrough technique that restores light sensitivity to previously unresponsive retinas

Study published in the April 27 online issue of Nature Neuroscience shows that the new technique enabled blind mice to successfully perform visually guided behavioral tasks, an unprecedented result that opens the way for clinical trials in humans

The approach pioneered at FMI could be an alternative to surgical transplantation of electrode arrays for the millions affected by blindness as a result of retinitis pigmentosa and late-stage macular degeneration

]]> Mon, 28 Apr 2008 17:10:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1214133_5.html Novartis International AG

Malaria affects 300 to 500 million people every year and is the biggest killer of children in Africa - every 30 seconds a child dies of malaria[1],[2]

Coartem, a highly-effective artemisinin-based fixed-dose combination, produces cure rates up to 95%[3],[4]

Since 2001, Novartis has provided more than 160 million treatments without profit to those most in need

Price reduction made possible through efficiency gains in producing Coartem

]]> Wed, 23 Apr 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1212224_5.html Novartis International AG

Novartis on track in 2008:

Pharmaceuticals net sales up 6% (-3% lc) as flagship brands and key regions help offset 19% decline in US from ongoing impact of generics and Zelnorm marketing suspension:

Sandoz benefits from fast-growing markets, particularly in Eastern Europe, as net sales rise 12% (+2% lc) and offset soft first-quarter sales in the US

Consumer Health with solid performance as net sales rise 14% (+5% lc) driven by growth in Animal Health, OTC and CIBA Vision

Vaccines and Diagnostics achieves dynamic net sales growth of 21% (+10% lc) while boosting investments in new meningitis vaccines and product portfolio

Novartis expects record sales and earnings in 2008 from continuing operations

]]> Mon, 21 Apr 2008 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1211012_5.html Novartis International AG

Phase II study extension shows 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment with oral FTY720[1]

New data demonstrate 89% of patients free from active brain lesions - the injury caused by MS - three years after starting treatment[1]

MS, a devastating disease causing progressive disability, affects 2.5 million people worldwide including many young adults[2]

FTY720 regulatory filings planned before end of 2009 in US and EU

]]> Tue, 15 Apr 2008 22:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1209064_5.html Novartis International AG

New data intended to support regulatory filings in 2008 with goal of expanding Stalevo indication to include treatment of early Parkinson's disease

Stalevo currently used only when levodopa/carbidopa loses therapeutic effect prior to next scheduled dose[2] (referred to as end-of-dose "wearing off")

Approximately 6.5 million people worldwide suffer from Parkinson's disease[3], a progressive and disabling neurological condition

]]> Tue, 15 Apr 2008 14:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1209170_5.html Novartis International AG

Glucocorticoids, commonly known as steroids, widely used to treat inflammatory conditions but can increase risk of osteoporotic fractures with up to 50% of patients on long-term therapy at risk[1],[2]

Study of more than 800 men and women shows higher bone mineral density with Aclasta than risedronate, a current established therapy[3]

Regulatory approval sought for treatment and prevention of glucocorticoid-induced osteoporosis in EU and US ]]> Fri, 11 Apr 2008 15:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1208659_5.html Novartis International AG

With launch of Phase III ATTRACT-1 trial in non-small cell lung cancer, Novartis Oncology assumes responsibility for development of ASA404 from Antisoma

Novel mechanism of action of ASA404 disrupts existing blood supply to tumors

Tumor-Vascular Disrupting Agent is one of six Novartis Oncology compounds in late-stage development for various solid tumors and blood cancers]]> Fri, 11 Apr 2008 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1208459_5.html Novartis International AG

Patients with inherited autoinflammatory conditions achieved long-lasting remission after treatment with ACZ885[1,2]

Human monoclonal antibody ACZ885 blocks interleukin 1ß, a key chemical messenger that causes inflammation and tissue destruction

Autoinflammatory diseases produce symptoms such as fever, joint pain and skin rash and can lead to severe complications

ACZ885 also being investigated for rheumatoid arthritis using innovative personalized approach to treatment]]> Tue, 8 Apr 2008 10:52:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1207396_5.html Novartis International AG

Novartis to first acquire 25% stake from Nestlé for USD 143.18 per share for approximately USD 11 billion, closing expected in second half of 2008

In optional second step, Novartis has exclusive right to acquire Nestlé's remaining 52% stake for a fixed price of USD 181 per share, totaling about USD 28 billion; Nestlé has right to require Novartis to buy this stake
Alcon the world leader in eye care with its pharmaceutical, surgical and consumer eye care products, and a highly-rated development pipeline

• Eye care market growing dynamically, driven by increase in age-related eye diseases, global expansion and novel therapies
  
• Strong strategic fit with complementary Novartis contact lens and ophtha pharmaceutical businesses; synergies expected to be realized in due time

]]> Mon, 7 Apr 2008 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200804/1206896_5.html Novartis International AG

New ALLAY study shows Rasilez alone reduced left ventricular hypertrophy (LVH) as effectively as current standard treatment[1]

LVH occurs in nearly a third of high blood pressure patients[2] and doubles risk of premature cardiovascular events or death

ALLAY is the latest in a series of studies to show potential of Rasilez in protecting against heart and kidney disease[3],[4]

Approved in more than 40 countries, Rasilez provides strong blood pressure reductions that last beyond 24 hours[5]

]]> Mon, 31 Mar 2008 20:02:00 +0200 http://cws.huginonline.com/N/134323/PR/200803/1205085_5.html Novartis International AG

New delivery system enables patient convenience

Priced 35% below the originator product, furthering patient access to Omnitrope, first follow-on version of a recombinant biotechnology drug ]]> Wed, 12 Mar 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200803/1200079_5.html Novartis International AG

Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen

Femara only member of aromatase inhibitor class with data demonstrating this potential benefit, as published in Journal of Clinical Oncology

Half of all breast cancer recurrences occur five or more years after diagnosis

Separate analysis published in Annals of Oncology affirms significant advantages of Femara when taken after standard tamoxifen therapy

]]> Mon, 10 Mar 2008 23:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200803/1199700_5.html Novartis International AG

Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus

Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR

Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008

Complete results to be submitted as late-breaking abstract for presentation at the American Society of Clinical Oncology meeting

]]> Thu, 28 Feb 2008 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1196020_5.html Novartis International AG

Shareholders approve 19% rise in dividend payment for 2007 to CHF 1.60 per share, represents payout ratio of 49% of net income from continuing operations

New CHF 10 billion share repurchase program receives approval

Ann Fudge elected to the Board of Directors; re-elected to the Board are Ulrich Lehner, Ph.D., Alexandre F. Jetzer, Pierre Landolt and Peter Burckhardt, M.D.



]]> Tue, 26 Feb 2008 16:46:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1195332_5.html Novartis International AG

Patients uncontrolled on metformin four times more likely to achieve blood sugar control on Eucreas compared to placebo

First single-tablet combination of a DPP-4 inhibitor and metformin approved for European countries

Eucreas results in no overall weight gain and low incidence of hypoglycemia

Both Eucreas and Galvus to be available to patients in the first EU countries in the next few weeks

]]> Mon, 25 Feb 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1194564_5.html Novartis International AG

Novartis Vaccines Institute for Global Health (NVGH) is the first institute with nonprofit mission established by a major vaccine manufacturer to exclusively focus on vaccines for diseases of the developing world

Research activities will draw upon Novartis Vaccines scientific expertise and cutting-edge technology platforms to advance new vaccines for serious unmet needs ]]> Fri, 22 Feb 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1194139_5.html Novartis International AG

Dividend payment for 2007 rises 19% to CHF 1.60 per share from 2006, represents a payout ratio of 49% of net income from continuing operations

New CHF 10 billion sixth share repurchase program proposed for approval

Ann Fudge recommended for election to the Board of Directors ]]> Fri, 1 Feb 2008 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1187378_5.html Novartis International AG

Approved for use in combination with the most common oral anti-diabetes medicines - metformin, thiazolidinediones or sulfonylureas

Galvus effectively lowers blood sugar levels and is well tolerated in a broad range of patients with type 2 diabetes ]]> Fri, 1 Feb 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200802/1187381_5.html Novartis International AG Thu, 31 Jan 2008 08:01:00 +0100 http://cws.huginonline.com/N/134323/PR/200801/1186906_5.html Novartis International AG

Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCT) in a single tablet[1]

Approved in more than 40 countries, Tekturna used alone lowers blood pressure for 24 hours and beyond[2],[3]

Data show combination of Tekturna and HCT resulted in significant additional blood pressure reductions compared to either drug alone[4]

Many patients not at goal and most require two or more medicines[5] - single-tablet combinations simplify treatment by reducing number of pills patients take[6] ]]> Mon, 21 Jan 2008 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200801/1183677_5.html Novartis International AG

Group results in 2007 set new record as net sales rise 8% (+3% in local currencies) to USD 39.8 billion and net income reaches USD 12.0 billion (+ 66%) with earnings per share up 68% to USD 5.15

Continuing operations now focused solely on healthcare

Launches progressing well for recently approved products - including Exforge, Tekturna/Rasilez, Lucentis, Exjade and Xolair - with 15 approvals in the US and the European Union

Increasing returns to shareholders while maintaining sound financial foundation

Novartis expects record results in 2008 from continuing operations on strong growth outlook for Sandoz, Vaccines and Diagnostics, and Consumer Health ]]> Thu, 17 Jan 2008 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200801/1182832_5.html Novartis International AG

Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y

Menveo stimulates broad immune response against meningococcal disease in infants from two months old ]]> Tue, 8 Jan 2008 23:23:00 +0100 http://cws.huginonline.com/N/134323/PR/200801/1180471_5.html Novartis International AG Mon, 17 Dec 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200712/1176484_5.html Novartis International AG Thu, 13 Dec 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200712/1175700_5.html Novartis International AG Sun, 9 Dec 2007 22:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200712/1174545_5.html Novartis International AG Sun, 2 Dec 2007 20:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200712/1172383_5.html Novartis International AG Fri, 30 Nov 2007 17:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1172289_5.html Novartis International AG Wed, 28 Nov 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1171279_5.html Novartis International AG Wed, 21 Nov 2007 15:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1170014_5.html Novartis International AG Mon, 19 Nov 2007 16:04:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1169462_5.html Novartis International AG Thu, 15 Nov 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1168580_5.html Novartis International AG Tue, 6 Nov 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200711/1166139_5.html Novartis International AG Mon, 29 Oct 2007 19:57:00 +0100 http://cws.huginonline.com/N/134323/PR/200710/1163903_5.html Novartis International AG Mon, 22 Oct 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200710/1161352_5.html Novartis International AG Thu, 18 Oct 2007 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200710/1160794_5.html Novartis International AG Fri, 5 Oct 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200710/1158103_5.html Novartis International AG Fri, 28 Sep 2007 13:13:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1156760_5.html Novartis International AG Fri, 28 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1156607_5.html Novartis International AG Thu, 27 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1156327_5.html Novartis International AG Mon, 24 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1155385_5.html Novartis International AG Fri, 21 Sep 2007 13:35:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1155247_5.html Novartis International AG Fri, 21 Sep 2007 13:35:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1155246_5.html Novartis International AG Tue, 18 Sep 2007 05:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1154028_5.html Novartis International AG Mon, 17 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1153741_5.html Novartis International AG Fri, 14 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1153481_5.html Novartis International AG Mon, 10 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1152398_5.html Novartis International AG Fri, 7 Sep 2007 19:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1152325_5.html Novartis International AG Wed, 5 Sep 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1151453_5.html Novartis International AG Mon, 3 Sep 2007 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1150584_5.html Novartis International AG Sun, 2 Sep 2007 11:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200709/1150590_5.html Novartis International AG Fri, 31 Aug 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1150279_5.html Novartis International AG Wed, 29 Aug 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1149615_5.html Novartis International AG Mon, 27 Aug 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1149047_5.html Novartis International AG Sat, 18 Aug 2007 00:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1147705_5.html Novartis International AG Thu, 16 Aug 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1146984_5.html Novartis International AG Fri, 10 Aug 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1145530_5.html Novartis International AG Mon, 6 Aug 2007 10:59:00 +0200 http://cws.huginonline.com/N/134323/PR/200708/1144199_5.html Novartis International AG Wed, 25 Jul 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1141673_5.html Novartis International AG Mon, 23 Jul 2007 14:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1141323_5.html Novartis International AG Fri, 20 Jul 2007 01:02:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1140965_5.html Novartis International AG Thu, 19 Jul 2007 20:25:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1140963_5.html Novartis International AG Thu, 19 Jul 2007 20:13:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1140962_5.html Novartis International AG Thu, 19 Jul 2007 20:13:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1140960_5.html Novartis International AG Tue, 17 Jul 2007 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1140047_5.html Novartis International AG Mon, 9 Jul 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1138163_5.html Novartis International AG Tue, 3 Jul 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1137173_5.html Novartis International AG Mon, 2 Jul 2007 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1136831_5.html Novartis International AG Mon, 2 Jul 2007 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200707/1136830_5.html Novartis International AG Mon, 25 Jun 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1135162_5.html Novartis International AG Fri, 22 Jun 2007 14:04:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1135070_5.html Novartis International AG Fri, 22 Jun 2007 14:03:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1135068_5.html Novartis International AG Thu, 21 Jun 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1134714_5.html Novartis International AG Fri, 15 Jun 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1133071_5.html Novartis International AG Wed, 13 Jun 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1132639_5.html Novartis International AG Mon, 11 Jun 2007 20:06:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1132363_5.html Novartis International AG Mon, 4 Jun 2007 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200706/1132897_5.html Novartis International AG Tue, 29 May 2007 21:46:00 +0200 http://cws.huginonline.com/N/134323/PR/200705/1129631_5.html Novartis International AG Mon, 21 May 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200705/1127684_5.html Novartis International AG Mon, 21 May 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200705/1127682_5.html Novartis International AG Tue, 8 May 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200705/1124782_5.html Novartis International AG Mon, 30 Apr 2007 09:08:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1122903_5.html Novartis International AG Fri, 27 Apr 2007 12:11:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1122731_5.html Novartis International AG Fri, 27 Apr 2007 07:37:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1122583_5.html Novartis International AG Thu, 26 Apr 2007 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1121970_5.html Novartis International AG Wed, 25 Apr 2007 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1121463_5.html Novartis International AG Wed, 25 Apr 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1121458_5.html Novartis International AG Mon, 23 Apr 2007 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1120505_5.html Novartis International AG Mon, 23 Apr 2007 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1120500_5.html Novartis International AG Thu, 19 Apr 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1119817_5.html Novartis International AG Tue, 17 Apr 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1119023_5.html Novartis International AG Thu, 12 Apr 2007 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1118349_5.html Novartis International AG Thu, 12 Apr 2007 07:29:00 +0200 http://cws.huginonline.com/N/134323/PR/200704/1118074_5.html Novartis International AG Fri, 30 Mar 2007 18:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200703/1116336_5.html Novartis International AG Mon, 26 Mar 2007 16:39:00 +0200 http://cws.huginonline.com/N/134323/PR/200703/1114292_5.html Novartis International AG Mon, 26 Mar 2007 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200703/1114185_5.html Novartis International AG Tue, 13 Mar 2007 14:05:00 +0100 http://cws.huginonline.com/N/134323/PR/200703/1111387_5.html Novartis International AG Tue, 6 Mar 2007 15:28:00 +0100 http://cws.huginonline.com/N/134323/PR/200703/1109992_5.html Novartis International AG Tue, 6 Mar 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200703/1109749_5.html Novartis International AG Sat, 3 Mar 2007 01:10:00 +0100 http://cws.huginonline.com/N/134323/PR/200703/1109430_5.html Novartis International AG Fri, 2 Mar 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200703/1109135_5.html Novartis International AG Mon, 26 Feb 2007 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1107681_5.html Novartis International AG Mon, 26 Feb 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1107676_5.html Novartis International AG Fri, 23 Feb 2007 12:33:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1107525_5.html Novartis International AG Thu, 15 Feb 2007 10:04:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1105441_5.html Novartis International AG Mon, 12 Feb 2007 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1104411_5.html Novartis International AG Fri, 9 Feb 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200702/1103588_5.html Novartis International AG Thu, 1 Feb 2007 20:28:35 +0100 http://cws.huginonline.com/N/134323/PR/200702/1101642_5.html Novartis International AG Thu, 25 Jan 2007 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200701/1099769_5.html Novartis International AG Wed, 24 Jan 2007 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200701/1099600_5.html Novartis International AG Thu, 18 Jan 2007 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200701/1098758_5.html Novartis International AG Thu, 18 Jan 2007 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200701/1098754_5.html Novartis International AG Wed, 17 Jan 2007 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200701/1098644_5.html Novartis International AG Fri, 22 Dec 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1094960_5.html Novartis International AG Thu, 14 Dec 2006 22:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1093411_5.html Novartis International AG Thu, 14 Dec 2006 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1093243_5.html Novartis International AG Thu, 14 Dec 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1093232_5.html Novartis International AG Mon, 11 Dec 2006 14:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1092474_5.html Novartis International AG Wed, 6 Dec 2006 23:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1091864_5.html Novartis International AG Wed, 6 Dec 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200612/1091731_5.html Novartis International AG Tue, 28 Nov 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200611/1090332_5.html Novartis International AG Mon, 20 Nov 2006 18:05:00 +0100 http://cws.huginonline.com/N/134323/PR/200611/1089243_5.html Novartis International AG Fri, 17 Nov 2006 15:03:46 +0100 http://cws.huginonline.com/N/134323/PR/200611/1088976_5.html Novartis International AG Fri, 17 Nov 2006 15:02:47 +0100 http://cws.huginonline.com/N/134323/PR/200611/1088975_5.html Novartis International AG Fri, 17 Nov 2006 15:01:05 +0100 http://cws.huginonline.com/N/134323/PR/200611/1088974_5.html Novartis International AG Mon, 13 Nov 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200611/1087811_5.html Novartis International AG Tue, 7 Nov 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200611/1086395_5.html Novartis International AG Mon, 6 Nov 2006 05:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200611/1086199_5.html Novartis International AG Wed, 25 Oct 2006 21:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1083687_5.html Novartis International AG Mon, 23 Oct 2006 14:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1082758_5.html Novartis International AG Fri, 20 Oct 2006 01:01:40 +0200 http://cws.huginonline.com/N/134323/PR/200610/1082376_5.html Novartis International AG Thu, 19 Oct 2006 08:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1082013_5.html Novartis International AG Thu, 19 Oct 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1082056_5.html Novartis International AG Thu, 19 Oct 2006 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1082045_5.html Novartis International AG Wed, 11 Oct 2006 17:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1080656_5.html Novartis International AG Wed, 4 Oct 2006 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1079164_5.html Novartis International AG Mon, 2 Oct 2006 15:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200610/1078903_5.html Novartis International AG Fri, 29 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1078440_5.html Novartis International AG Thu, 28 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1078132_5.html Novartis International AG Thu, 28 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1077940_5.html Novartis International AG Wed, 27 Sep 2006 16:43:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1078075_5.html Novartis International AG Thu, 21 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1076869_5.html Novartis International AG Tue, 19 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1075826_5.html Novartis International AG Sat, 16 Sep 2006 22:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1075407_5.html Novartis International AG Thu, 14 Sep 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1075250_5.html Novartis International AG Wed, 13 Sep 2006 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1075246_5.html Novartis International AG Sun, 3 Sep 2006 08:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200609/1072840_5.html Novartis International AG Wed, 30 Aug 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1072209_5.html Novartis International AG Tue, 29 Aug 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1071973_5.html Novartis International AG Thu, 17 Aug 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1069550_5.html Novartis International AG Wed, 16 Aug 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1069333_5.html Novartis International AG Mon, 14 Aug 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1068858_5.html Novartis International AG Tue, 8 Aug 2006 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200608/1068580_5.html Novartis International AG Fri, 28 Jul 2006 16:14:23 +0200 http://cws.huginonline.com/N/134323/PR/200607/1066400_5.html Novartis International AG Tue, 25 Jul 2006 16:00:50 +0200 http://cws.huginonline.com/N/134323/PR/200607/1065640_5.html Novartis International AG Mon, 24 Jul 2006 18:00:05 +0200 http://cws.huginonline.com/N/134323/PR/200607/1065489_5.html Novartis International AG Wed, 19 Jul 2006 16:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200607/1064533_5.html Novartis International AG Tue, 18 Jul 2006 14:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200607/1064656_5.html Novartis International AG Mon, 17 Jul 2006 07:01:52 +0200 http://cws.huginonline.com/N/134323/PR/200607/1064053_5.html Novartis International AG Fri, 14 Jul 2006 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200607/1063796_5.html Novartis International AG Mon, 3 Jul 2006 12:16:03 +0200 http://cws.huginonline.com/N/134323/PR/200607/1061565_5.html Novartis International AG Mon, 26 Jun 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1059811_5.html Novartis International AG Wed, 14 Jun 2006 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1056533_5.html Novartis International AG Tue, 13 Jun 2006 14:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1056044_5.html Novartis International AG Tue, 13 Jun 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1055692_5.html Novartis International AG Tue, 13 Jun 2006 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1056015_5.html Novartis International AG Wed, 7 Jun 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1054269_5.html Novartis International AG Tue, 6 Jun 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1054087_5.html Novartis International AG Sun, 4 Jun 2006 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1054010_5.html Novartis International AG Sat, 3 Jun 2006 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200606/1053996_5.html Novartis International AG Wed, 31 May 2006 10:30:36 +0200 http://cws.huginonline.com/N/134323/PR/200605/1053382_5.html Novartis International AG Tue, 23 May 2006 10:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200605/1052419_5.html Novartis International AG Fri, 19 May 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200605/1051807_5.html Novartis International AG Wed, 17 May 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200605/1051497_5.html Novartis International AG Wed, 17 May 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200605/1051483_5.html Novartis International AG Wed, 10 May 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200605/1050165_5.html Novartis International AG Thu, 4 May 2006 16:00:51 +0200 http://cws.huginonline.com/N/134323/PR/200605/1049147_5.html Novartis International AG

- Regulatory submission includes results from more than 5,000 hypertensive patients]]> Thu, 27 Apr 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1047147_5.html Novartis International AG Mon, 24 Apr 2006 07:01:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1046164_5.html Novartis International AG Thu, 20 Apr 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1045693_5.html Novartis International AG Wed, 19 Apr 2006 18:28:38 +0200 http://cws.huginonline.com/N/134323/PR/200604/1045686_5.html Novartis International AG Tue, 18 Apr 2006 14:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1045355_5.html Novartis International AG Mon, 10 Apr 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1044420_5.html Novartis International AG Thu, 6 Apr 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200604/1043685_5.html Novartis International AG Mon, 3 Apr 2006 18:20:20 +0200 http://cws.huginonline.com/N/134323/PR/200604/1042977_5.html Novartis International AG Thu, 30 Mar 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200603/1041987_5.html Novartis International AG Wed, 29 Mar 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200603/1041772_5.html Novartis International AG Wed, 29 Mar 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200603/1041770_5.html Novartis International AG Mon, 27 Mar 2006 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200603/1041252_5.html Novartis International AG Fri, 24 Mar 2006 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200603/1041002_5.html Novartis International AG Mon, 20 Mar 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200603/1039925_5.html Novartis International AG Thu, 16 Mar 2006 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200603/1039829_5.html Novartis International AG
tartrate) has been granted European marketing authorization by the European
Commission for the symptomatic treatment of mild to moderately severe dementia in
patients with idiopathic Parkinson's disease (PD) in all 25 European member states.
]]> Tue, 14 Mar 2006 15:34:39 +0100 http://cws.huginonline.com/N/134323/PR/200603/1039161_5.html Novartis International AG Fri, 3 Mar 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200603/1037376_5.html Novartis International AG Thu, 2 Mar 2006 07:24:42 +0100 http://cws.huginonline.com/N/134323/PR/200603/1037374_5.html Novartis International AG Tue, 28 Feb 2006 15:21:14 +0100 http://cws.huginonline.com/N/134323/PR/200602/1037104_5.html Novartis International AG Fri, 24 Feb 2006 22:35:00 +0100 http://cws.huginonline.com/N/134323/PR/200602/1036635_5.html Novartis International AG Tue, 21 Feb 2006 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200602/1035836_5.html Novartis International AG Fri, 17 Feb 2006 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200602/1035622_5.html Novartis International AG Tue, 7 Feb 2006 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200602/1033079_5.html Novartis International AG Mon, 6 Feb 2006 18:09:08 +0100 http://cws.huginonline.com/N/134323/PR/200602/1033141_5.html Novartis International AG Fri, 3 Feb 2006 07:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200602/1032781_5.html Novartis International AG Mon, 30 Jan 2006 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1031793_5.html Novartis International AG Fri, 27 Jan 2006 12:57:02 +0100 http://cws.huginonline.com/N/134323/PR/200601/1031718_5.html Novartis International AG Thu, 19 Jan 2006 07:09:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1030490_5.html Novartis International AG Wed, 18 Jan 2006 15:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1030389_5.html Novartis International AG Mon, 16 Jan 2006 16:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1030092_5.html Novartis International AG Tue, 10 Jan 2006 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1029300_5.html Novartis International AG Tue, 3 Jan 2006 14:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1028538_5.html Novartis International AG Mon, 2 Jan 2006 16:20:00 +0100 http://cws.huginonline.com/N/134323/PR/200601/1028416_5.html Novartis International AG Wed, 21 Dec 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1026889_5.html Novartis International AG Sun, 18 Dec 2005 21:37:51 +0100 http://cws.huginonline.com/N/134323/PR/200512/1026292_5.html Novartis International AG Fri, 16 Dec 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1025912_5.html Novartis International AG Thu, 15 Dec 2005 12:05:46 +0100 http://cws.huginonline.com/N/134323/PR/200512/1025752_5.html Novartis International AG Tue, 13 Dec 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1025081_5.html Novartis International AG Tue, 13 Dec 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1025079_5.html Novartis International AG Mon, 12 Dec 2005 14:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1025134_5.html Novartis International AG Thu, 8 Dec 2005 16:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1024699_5.html Novartis International AG Tue, 6 Dec 2005 18:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1024431_5.html Novartis International AG Tue, 6 Dec 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200512/1024307_5.html Novartis International AG Mon, 28 Nov 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200511/1023055_5.html Novartis International AG Mon, 14 Nov 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200511/1020875_5.html Novartis International AG Wed, 9 Nov 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200511/1020088_5.html Novartis International AG Mon, 7 Nov 2005 22:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200511/1019970_5.html Novartis International AG Thu, 3 Nov 2005 08:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200511/1019429_5.html Novartis International AG Thu, 3 Nov 2005 07:58:06 +0100 http://cws.huginonline.com/N/134323/PR/200511/1019451_5.html Novartis International AG Mon, 31 Oct 2005 10:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200510/1018774_5.html Novartis International AG Thu, 27 Oct 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200510/1018069_5.html Novartis International AG Wed, 19 Oct 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200510/1016599_5.html Novartis International AG Tue, 18 Oct 2005 11:23:36 +0200 http://cws.huginonline.com/N/134323/PR/200510/1016467_5.html Novartis International AG Mon, 17 Oct 2005 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200510/1016482_5.html Novartis International AG Fri, 14 Oct 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200510/1015473_5.html Novartis International AG Sat, 1 Oct 2005 08:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200510/1013921_5.html Novartis International AG Fri, 30 Sep 2005 00:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1013736_5.html Novartis International AG Tue, 20 Sep 2005 07:29:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1012406_5.html Novartis International AG Mon, 19 Sep 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1012245_5.html Novartis International AG Mon, 19 Sep 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1012241_5.html Novartis International AG Tue, 13 Sep 2005 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1013636_5.html Novartis International AG Wed, 7 Sep 2005 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1013638_5.html Novartis International AG Thu, 1 Sep 2005 07:20:00 +0200 http://cws.huginonline.com/N/134323/PR/200509/1009303_5.html Novartis International AG Wed, 31 Aug 2005 23:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200508/1009286_5.html Novartis International AG Mon, 29 Aug 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200508/1008779_5.html Novartis International AG Thu, 18 Aug 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200508/1007014_5.html Novartis International AG Wed, 3 Aug 2005 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200508/1009397_5.html Novartis International AG Thu, 28 Jul 2005 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1004045_5.html Novartis International AG Thu, 28 Jul 2005 19:07:37 +0200 http://cws.huginonline.com/N/134323/PR/200507/1004258_5.html Novartis International AG Thu, 28 Jul 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1004091_5.html Novartis International AG Wed, 27 Jul 2005 10:59:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1003942_5.html Novartis International AG Thu, 21 Jul 2005 14:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1003309_5.html Novartis International AG Thu, 21 Jul 2005 10:52:01 +0200 http://cws.huginonline.com/N/134323/PR/200507/1003329_5.html Novartis International AG Tue, 19 Jul 2005 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1003039_5.html Novartis International AG Mon, 18 Jul 2005 18:41:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1002762_5.html Novartis International AG

Portfolio of brands - led by Excedrin® - acquired for USD 660 million]]> Thu, 14 Jul 2005 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1002514_5.html Novartis International AG Thu, 14 Jul 2005 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1002329_5.html Novartis International AG

Pre-planned subset analyses show Femara reduces risk of cancer returning by up to 30% in node-positive and chemotherapy-treated patients]]> Mon, 11 Jul 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1001822_5.html Novartis International AG Fri, 8 Jul 2005 20:37:14 +0200 http://cws.huginonline.com/N/134323/PR/200507/1001858_5.html Novartis International AG Wed, 6 Jul 2005 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1001607_5.html Novartis International AG Tue, 5 Jul 2005 13:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1001372_5.html Novartis International AG Fri, 1 Jul 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200507/1001039_5.html Novartis International AG

RSV infects 50-70% of infants during their first year of life and is an area of high unmet medical need]]> Thu, 30 Jun 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/1000677_5.html Novartis International AG Wed, 22 Jun 2005 07:29:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/999551_5.html Novartis International AG Tue, 21 Jun 2005 16:44:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/999521_5.html Novartis International AG Tue, 21 Jun 2005 13:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/999409_5.html Novartis International AG Mon, 20 Jun 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/999118_5.html Novartis International AG

Diovan provides a new treatment option for more than 4.5 million Europeans with heart failure ]]> Mon, 13 Jun 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/998132_5.html Novartis International AG Wed, 8 Jun 2005 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/1009391_5.html Novartis International AG Tue, 7 Jun 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/997404_5.html Novartis International AG

East African Botanicals scale-up efforts boosted by financial and technical support from Novartis

Local economies benefit from job creation in agricultural and manufacturing sectors ]]> Mon, 6 Jun 2005 11:30:35 +0200 http://cws.huginonline.com/N/134323/PR/200506/997306_5.html Novartis International AG Thu, 2 Jun 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200506/996839_5.html Novartis International AG Fri, 27 May 2005 13:19:01 +0200 http://cws.huginonline.com/N/134323/PR/200505/996147_5.html Novartis International AG Thu, 26 May 2005 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/996037_5.html Novartis International AG Thu, 26 May 2005 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/1009385_5.html Novartis International AG Mon, 23 May 2005 22:08:47 +0200 http://cws.huginonline.com/N/134323/PR/200505/995507_5.html Novartis International AG Mon, 23 May 2005 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/995472_5.html Novartis International AG Thu, 19 May 2005 11:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/994911_5.html Novartis International AG Wed, 18 May 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/994719_5.html Novartis International AG Sun, 15 May 2005 19:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/994461_5.html Novartis International AG Fri, 13 May 2005 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/994428_5.html Novartis International AG Fri, 13 May 2005 22:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/994424_5.html Novartis International AG Mon, 9 May 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/993017_5.html Novartis International AG Tue, 3 May 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/992462_5.html Novartis International AG Tue, 3 May 2005 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200505/992453_5.html Novartis International AG

- Novartis continues unprecedented production scale-up to meet rapidly increasing demand estimates ]]> Tue, 26 Apr 2005 18:08:29 +0200 http://cws.huginonline.com/N/134323/PR/200504/991237_5.html Novartis International AG

70% of Country General Managers have been nominated
]]> Tue, 26 Apr 2005 09:35:00 +0200 http://cws.huginonline.com/N/134323/PR/200504/991038_5.html Novartis International AG Thu, 21 Apr 2005 07:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200504/990207_5.html Novartis International AG Thu, 21 Apr 2005 07:14:00 +0200 http://cws.huginonline.com/N/134323/PR/200504/990225_5.html Novartis International AG Wed, 13 Apr 2005 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200504/988894_5.html Novartis International AG Fri, 8 Apr 2005 09:32:51 +0200 http://cws.huginonline.com/N/134323/PR/200504/988318_5.html Novartis International AG

Independent data monitoring board recommends CONFIRM 1 trial to continue to allow analysis of overall survival (Second Primary Endpoint)]]> Mon, 21 Mar 2005 06:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200503/985846_5.html Novartis International AG Thu, 10 Mar 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200503/984110_5.html Novartis International AG Fri, 4 Mar 2005 07:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200503/983394_5.html Novartis International AG

Driven by dynamic business performance in 2004, annual dividend increases to CHF 1.05 per share (+5%)

New share buyback program of up to CHF 4 billion and reduction of share capital return further liquidity to shareholders

High single digit growth rates for Group and Pharmaceuticals expected to drive further market share gains in 2005 ]]> Tue, 1 Mar 2005 14:13:50 +0100 http://cws.huginonline.com/N/134323/PR/200503/982764_5.html Novartis International AG Mon, 28 Feb 2005 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/982550_5.html Novartis International AG Mon, 21 Feb 2005 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/981623_5.html Novartis International AG Mon, 21 Feb 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/981486_5.html Novartis International AG Tue, 15 Feb 2005 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/980489_5.html Novartis International AG Mon, 7 Feb 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/979042_5.html Novartis International AG Fri, 4 Feb 2005 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200502/978908_5.html Novartis International AG Fri, 28 Jan 2005 11:03:50 +0100 http://cws.huginonline.com/N/134323/PR/200501/977901_5.html Novartis International AG Wed, 26 Jan 2005 19:15:22 +0100 http://cws.huginonline.com/N/134323/PR/200501/977618_5.html Novartis International AG Tue, 25 Jan 2005 07:30:32 +0100 http://cws.huginonline.com/N/134323/PR/200501/977209_5.html Novartis International AG Thu, 20 Jan 2005 17:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200501/976799_5.html Novartis International AG Thu, 20 Jan 2005 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200501/976579_5.html Novartis International AG Thu, 20 Jan 2005 06:55:00 +0100 http://cws.huginonline.com/N/134323/PR/200501/976581_5.html Novartis International AG Thu, 20 Jan 2005 06:55:00 +0100 http://cws.huginonline.com/N/134323/PR/200501/976580_5.html Novartis International AG Thu, 20 Jan 2005 00:36:40 +0100 http://cws.huginonline.com/N/134323/PR/200501/976583_5.html Novartis International AG Thu, 6 Jan 2005 14:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200501/975155_5.html Novartis International AG Thu, 23 Dec 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/973471_5.html Novartis International AG Wed, 22 Dec 2004 14:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/973414_5.html Novartis International AG Fri, 17 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/972662_5.html Novartis International AG
Patients were also able to cope better with activities of daily living ]]> Thu, 9 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971636_5.html Novartis International AG Tue, 7 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971414_5.html Novartis International AG Mon, 6 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971324_5.html Novartis International AG Mon, 6 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971321_5.html Novartis International AG Thu, 2 Dec 2004 15:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971110_5.html Novartis International AG Wed, 1 Dec 2004 17:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/971008_5.html Novartis International AG
Paves the way for further approvals of this indication throughout the EU]]> Wed, 1 Dec 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200412/970821_5.html Novartis International AG Tue, 30 Nov 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200411/970628_5.html Novartis International AG Thu, 18 Nov 2004 10:24:05 +0100 http://cws.huginonline.com/N/134323/PR/200411/969585_5.html Novartis International AG Thu, 18 Nov 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200411/1011592_5.html Novartis International AG Mon, 15 Nov 2004 11:47:28 +0100 http://cws.huginonline.com/N/134323/PR/200411/969086_5.html Novartis International AG Mon, 1 Nov 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200411/1011598_5.html Novartis International AG Wed, 27 Oct 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200410/1011607_5.html Novartis International AG Wed, 27 Oct 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200410/1011602_5.html Novartis International AG Tue, 26 Oct 2004 00:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200410/1011608_5.html Novartis International AG Thu, 21 Oct 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200410/1011830_5.html Novartis International AG Mon, 4 Oct 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200410/1011827_5.html Novartis International AG Thu, 30 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011622_5.html Novartis International AG Mon, 27 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011623_5.html Novartis International AG Fri, 24 Sep 2004 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011625_5.html Novartis International AG Wed, 22 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011626_5.html Novartis International AG Tue, 7 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011628_5.html Novartis International AG Fri, 3 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011629_5.html Novartis International AG Thu, 2 Sep 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011821_5.html Novartis International AG Wed, 1 Sep 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200409/1011631_5.html Novartis International AG Tue, 31 Aug 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011633_5.html Novartis International AG Mon, 30 Aug 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011634_5.html Novartis International AG Mon, 23 Aug 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011635_5.html Novartis International AG Fri, 20 Aug 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011637_5.html Novartis International AG Mon, 16 Aug 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011817_5.html Novartis International AG Thu, 12 Aug 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011638_5.html Novartis International AG Mon, 9 Aug 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200408/1011788_5.html Novartis International AG Fri, 30 Jul 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200407/1011786_5.html Novartis International AG Tue, 20 Jul 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200407/1011784_5.html Novartis International AG Wed, 14 Jul 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200407/1011783_5.html Novartis International AG Mon, 5 Jul 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200407/1011781_5.html Novartis International AG Fri, 2 Jul 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200407/1011779_5.html Novartis International AG Wed, 30 Jun 2004 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011812_5.html Novartis International AG Tue, 29 Jun 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011778_5.html Novartis International AG Mon, 28 Jun 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011776_5.html Novartis International AG Thu, 24 Jun 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011774_5.html Novartis International AG Mon, 14 Jun 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011765_5.html Novartis International AG Wed, 9 Jun 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011963_5.html Novartis International AG Tue, 8 Jun 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011762_5.html Novartis International AG Mon, 7 Jun 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200406/1011761_5.html Novartis International AG Fri, 21 May 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/947641_5.html Novartis International AG Tue, 18 May 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/947643_5.html Novartis International AG Tue, 18 May 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/1011758_5.html Novartis International AG Fri, 14 May 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/1011754_5.html Novartis International AG Wed, 12 May 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/1011750_5.html Novartis International AG Mon, 10 May 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/1011748_5.html Novartis International AG Mon, 10 May 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200405/1011746_5.html Novartis International AG Sun, 25 Apr 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200404/1011745_5.html Novartis International AG Fri, 23 Apr 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200404/1011743_5.html Novartis International AG Thu, 22 Apr 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200404/1011742_5.html Novartis International AG Wed, 7 Apr 2004 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200404/1011962_5.html Novartis International AG Fri, 2 Apr 2004 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200404/1011738_5.html Novartis International AG Tue, 23 Mar 2004 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200403/1011733_5.html Novartis International AG Fri, 12 Mar 2004 07:55:00 +0100 http://cws.huginonline.com/N/134323/PR/200403/937772_5.html Novartis International AG Fri, 5 Mar 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200403/1011731_5.html Novartis International AG Mon, 1 Mar 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200403/936239_5.html Novartis International AG Thu, 26 Feb 2004 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/1011728_5.html Novartis International AG Tue, 24 Feb 2004 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/1011727_5.html Novartis International AG Tue, 17 Feb 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/1011726_5.html Novartis International AG Fri, 13 Feb 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/934203_5.html Novartis International AG Wed, 11 Feb 2004 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/1011725_5.html Novartis International AG Tue, 10 Feb 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/933583_5.html Novartis International AG Thu, 5 Feb 2004 08:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/932973_5.html Novartis International AG Wed, 4 Feb 2004 07:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200402/932778_5.html Novartis International AG Fri, 30 Jan 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/1011722_5.html Novartis International AG Fri, 30 Jan 2004 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/932350_5.html Novartis International AG Fri, 23 Jan 2004 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/1011961_5.html Novartis International AG Thu, 22 Jan 2004 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/1012053_5.html Novartis International AG Thu, 22 Jan 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/1011720_5.html Novartis International AG Thu, 22 Jan 2004 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/1011711_5.html Novartis International AG Thu, 22 Jan 2004 07:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/931477_5.html Novartis International AG Tue, 20 Jan 2004 16:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/931297_5.html Novartis International AG Fri, 16 Jan 2004 10:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200401/930917_5.html Novartis International AG Tue, 16 Dec 2003 07:28:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/928373_5.html Novartis International AG Thu, 11 Dec 2003 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/927878_5.html Novartis International AG Tue, 9 Dec 2003 09:40:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/927630_5.html Novartis International AG Mon, 8 Dec 2003 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/1011694_5.html Novartis International AG Mon, 8 Dec 2003 09:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/1011693_5.html Novartis International AG Wed, 3 Dec 2003 17:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/927170_5.html Novartis International AG Mon, 1 Dec 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200312/1011647_5.html Novartis International AG Thu, 27 Nov 2003 08:15:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/926428_5.html Novartis International AG Fri, 21 Nov 2003 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011804_5.html Novartis International AG Wed, 19 Nov 2003 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011802_5.html Novartis International AG Wed, 19 Nov 2003 05:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/925519_5.html Novartis International AG Mon, 17 Nov 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011646_5.html Novartis International AG Mon, 10 Nov 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011644_5.html Novartis International AG Mon, 10 Nov 2003 08:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011799_5.html Novartis International AG Thu, 6 Nov 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200311/1011643_5.html Novartis International AG Thu, 30 Oct 2003 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200310/922709_5.html Novartis International AG Thu, 23 Oct 2003 17:31:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/921897_5.html Novartis International AG Tue, 21 Oct 2003 09:18:44 +0200 http://cws.huginonline.com/N/134323/PR/200310/921303_5.html Novartis International AG Mon, 20 Oct 2003 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/921061_5.html Novartis International AG Thu, 16 Oct 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/920738_5.html Novartis International AG Fri, 10 Oct 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/920068_5.html Novartis International AG Thu, 9 Oct 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/1011642_5.html Novartis International AG Thu, 9 Oct 2003 08:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/919953_5.html Novartis International AG Wed, 8 Oct 2003 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/919780_5.html Novartis International AG Fri, 3 Oct 2003 22:45:00 +0200 http://cws.huginonline.com/N/134323/PR/200310/919513_5.html Novartis International AG Tue, 23 Sep 2003 23:16:46 +0200 http://cws.huginonline.com/N/134323/PR/200309/918427_5.html Novartis International AG Tue, 23 Sep 2003 00:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200309/1011393_5.html Novartis International AG Tue, 16 Sep 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200309/917447_5.html Novartis International AG Tue, 2 Sep 2003 11:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200309/916029_5.html Novartis International AG Tue, 2 Sep 2003 00:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200309/1011630_5.html Novartis International AG Mon, 1 Sep 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200309/915818_5.html Novartis International AG Fri, 29 Aug 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/915580_5.html Novartis International AG Thu, 28 Aug 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/1012042_5.html Novartis International AG Thu, 28 Aug 2003 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/1011370_5.html Novartis International AG Thu, 28 Aug 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/915429_5.html Novartis International AG Tue, 19 Aug 2003 07:30:08 +0200 http://cws.huginonline.com/N/134323/PR/200308/914254_5.html Novartis International AG Mon, 18 Aug 2003 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/1010495_5.html Novartis International AG Fri, 1 Aug 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200308/1009186_5.html Novartis International AG Thu, 24 Jul 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200307/911663_5.html Novartis International AG Wed, 23 Jul 2003 07:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200307/911543_5.html Novartis International AG Mon, 21 Jul 2003 09:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200307/1010493_5.html Novartis International AG Thu, 17 Jul 2003 07:42:51 +0200 http://cws.huginonline.com/N/134323/PR/200307/911074_5.html Novartis International AG Thu, 10 Jul 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200307/910543_5.html Novartis International AG Thu, 10 Jul 2003 07:27:04 +0200 http://cws.huginonline.com/N/134323/PR/200307/910546_5.html Novartis International AG Wed, 25 Jun 2003 07:15:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/908998_5.html Novartis International AG Mon, 23 Jun 2003 08:22:06 +0200 http://cws.huginonline.com/N/134323/PR/200306/908721_5.html Novartis International AG Mon, 23 Jun 2003 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010487_5.html Novartis International AG Fri, 20 Jun 2003 08:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1011791_5.html Novartis International AG Wed, 18 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010098_5.html Novartis International AG Mon, 16 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010089_5.html Novartis International AG

Basel, 13 June 2003 - Novartis announced today that the U.S. Food and DrugAdministration (FDA) has approved Stalevo(TM) (carbidopa, levodopa and entacapone)tablets, for the treatment of patients with idiopathic Parkinson's disease (PD) whoexperience signs and symptoms of end-of-dose "wearing-off."]]> Fri, 13 Jun 2003 07:50:05 +0200 http://cws.huginonline.com/N/134323/PR/200306/907565_5.html Novartis International AG Thu, 12 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010084_5.html Novartis International AG Wed, 11 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010078_5.html Novartis International AG Tue, 10 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010077_5.html Novartis International AG Tue, 3 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010075_5.html Novartis International AG Tue, 3 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010070_5.html Novartis International AG Tue, 3 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010068_5.html Novartis International AG Mon, 2 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010067_5.html Novartis International AG Mon, 2 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010066_5.html Novartis International AG Mon, 2 Jun 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200306/1010062_5.html Novartis International AG Thu, 29 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010059_5.html Novartis International AG Wed, 28 May 2003 16:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/905827_5.html Novartis International AG Wed, 28 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010057_5.html Novartis International AG Tue, 27 May 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/905497_5.html Novartis International AG Fri, 23 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010056_5.html Novartis International AG Wed, 21 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010055_5.html Novartis International AG Tue, 20 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010054_5.html Novartis International AG Tue, 20 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010050_5.html Novartis International AG Fri, 16 May 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/1010048_5.html Novartis International AG Fri, 9 May 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200305/902926_5.html Novartis International AG Wed, 30 Apr 2003 08:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/901262_5.html Novartis International AG Fri, 25 Apr 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/1011952_5.html Novartis International AG Tue, 15 Apr 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/1010045_5.html Novartis International AG Mon, 14 Apr 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/899235_5.html Novartis International AG Thu, 10 Apr 2003 17:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/899065_5.html Novartis International AG Wed, 9 Apr 2003 07:34:15 +0200 http://cws.huginonline.com/N/134323/PR/200304/898714_5.html Novartis International AG

Nicht-steroidale Creme von Novartis gegen Ekzem wird Anfang April erhältlich

Basel, 7. April 2003 - Novartis gibt heute bekannt, dass das Schweizerische Heilmittelinstitut Swissmedic ihr die Marktzulassung für die neue nicht-steroidale Creme Elidel® (Pimecrolimus) 1% erteilt hat. Elidel ist bei Patienten ab dem Alter von 2 Jahren mit leichtem bis mittelschwerem atopischem Ekzem indiziert, für die kurzzeitige Behandlung von Anzeichen und Symptomen und für die intermittierende Langzeitbehandlung. ]]> Mon, 7 Apr 2003 07:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/898214_5.html Novartis International AG Thu, 3 Apr 2003 08:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/897775_5.html Novartis International AG Tue, 1 Apr 2003 12:00:00 +0200 http://cws.huginonline.com/N/134323/PR/200304/1009417_5.html Novartis International AG

New Findings from LIPS presented at ACC

Basel, Switzerland, 31 March, 2003 - Lescol® (fluvastatin sodium) administered immediately following first angioplasty reduces the risk of fatal and non-fatal serious cardiac events in high-risk patients with more than one blocked coronary artery down to that of lower-risk patients with only one blocked artery, according to a new analysis of the Lescol Intervention Prevention Study (LIPS).1 These findings were presented at ACC 03 - the 52nd Annual Scientific Session of the American College of Cardiology by researchers from the Erasmus Medical Centre, University Hospital, Rotterdam, The Netherlands. ]]> Mon, 31 Mar 2003 10:30:00 +0200 http://cws.huginonline.com/N/134323/PR/200303/897358_5.html Novartis International AG

Agreement provides Novartis worldwide co-promotion excluding Japan

Basel, 28 March 2003 - Novartis Pharma AG has signed an agreement to license IL-1 Trap compound from Regeneron, a Tarrytown NY based, publicly quoted, biopharmaceutical company developing therapies for rheumatoid arthritis, cancer, allergy and asthma. Under the terms of the agreement, Novartis will purchase $48 million of newly issued Regeneron common stock. In addition Novartis will pay Regeneron $27 million upon closing for its development activities. Further payments are contingent on meeting approval and sales milestones. ]]> Fri, 28 Mar 2003 14:54:27 +0100 http://cws.huginonline.com/N/134323/PR/200303/897295_5.html Novartis International AG Wed, 26 Mar 2003 07:42:32 +0100 http://cws.huginonline.com/N/134323/PR/200303/896847_5.html Novartis International AG

Strategic acquisition further strengthens Novartis' competitive primary care portfolio ]]> Tue, 18 Mar 2003 08:00:53 +0100 http://cws.huginonline.com/N/134323/PR/200303/895852_5.html Novartis International AG Fri, 14 Mar 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200303/1009386_5.html Novartis International AG Thu, 13 Mar 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200303/1009383_5.html Novartis International AG Wed, 12 Mar 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200303/1009380_5.html Novartis International AG Tue, 4 Mar 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200303/1009370_5.html Novartis International AG Sat, 1 Mar 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200303/1009183_5.html Novartis International AG

CPMP positive on data to expand current indication; data confirm long-term efficacy and safety of Zometa/show breast cancer patients have additional 20% reduced risk of bone complications compared to those treated with Pamidronate; EU approval moves closer ]]> Tue, 25 Feb 2003 07:45:00 +0100 http://cws.huginonline.com/N/134323/PR/200302/893045_5.html Novartis International AG Mon, 24 Feb 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200302/1009365_5.html Novartis International AG Wed, 19 Feb 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200302/1009363_5.html Novartis International AG Wed, 12 Feb 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200302/1009344_5.html Novartis International AG

Continuation of strategic focus on introducing new medicines and resourcing key growth drivers ]]> Wed, 12 Feb 2003 08:53:25 +0100 http://cws.huginonline.com/N/134323/PR/200302/891266_5.html Novartis International AG Thu, 30 Jan 2003 07:30:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/889933_5.html Novartis International AG Mon, 27 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009339_5.html Novartis International AG Sat, 25 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009336_5.html Novartis International AG Thu, 23 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1011990_5.html Novartis International AG Thu, 23 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009328_5.html Novartis International AG Tue, 21 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009221_5.html Novartis International AG Fri, 17 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009199_5.html Novartis International AG Thu, 16 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1011943_5.html Novartis International AG Thu, 16 Jan 2003 12:00:00 +0100 http://cws.huginonline.com/N/134323/PR/200301/1009193_5.html Novartis International AG